Literature DB >> 8877127

Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.

D C Powers1, E D Kilbourne, B E Johansson.   

Abstract

Little information is available on the potential role of antibody to influenza virus neuraminidase (NA) in vaccine-induced immunity. In the present study, serologic responses to the N1Texas/91 and N2Beijing/92 NA components of trivalent inactivated influenza virus vaccine were measured by NA inhibition (NI) and enzyme-linked immunosorbent assay (ELISA), and the results for adults aged 18 to 45 (young) or > or = 65 (elderly) years were compared. The two age groups had comparable rates (32 to 50%) of NI response. In contrast, ELISA immunoglobulin G (IgG) antibody responses to N1 and N2 NAs occurred in 70 to 71 and 67 to 83%, respectively, of young subjects but in only 3 to 18 and 18 to 35%, respectively, of elderly subjects. prevaccination mean ELISA IgG and IgA NA antibody titers were generally lower for the young adults than they were for the elderly, whereas the corresponding NI titers were comparable. In young adults, plaque size-reducing NA antibody increases were positively associated with ELISA but not with NI antibody increases. There were no apparent age-related differences in the immunoglobulin isotype distribution of the anti-NA response, with IgG being the dominant class and IgG1 the dominant subclass of serum antibody. Anti-hemagglutinin antibody responses to H1Texas/91 and H3Beijing/92 were greater in magnitude and frequency than the corresponding NA-specific responses to N1Texas/91 and N2Beijing/92 when measured by hemagglutination inhibition and NI, respectively, but not when measured by ELISA. The discordance between NI and ELISA for measurement of NA-specific vaccine responses may reflect the relative insensitivity of NI in discriminating differences when initial antibody titers are low.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877127      PMCID: PMC170398          DOI: 10.1128/cdli.3.5.511-516.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  37 in total

1.  Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

Authors:  R B Couch; J A Kasel; J L Gerin; J L Schulman; E D Kilbourne
Journal:  J Infect Dis       Date:  1974-04       Impact factor: 5.226

Review 2.  Biological activities of immunoglobulins of different classes and subclasses.

Authors:  H L Spiegelberg
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

3.  Influenza neuraminidase antibody patterns of man.

Authors:  A P Kendal; E Minuse; H F Maassab; A V Hennessy; F M Davenport
Journal:  Am J Epidemiol       Date:  1973-08       Impact factor: 4.897

4.  Effect of neuraminidase antibody on Hong Kong influenza.

Authors:  A S Monto; A P Kendal
Journal:  Lancet       Date:  1973-03-24       Impact factor: 79.321

5.  Association of serum anti-neuraminidase antibody with resistance to influenza in man.

Authors:  B R Murphy; J A Kasel; R M Chanock
Journal:  N Engl J Med       Date:  1972-06-22       Impact factor: 91.245

6.  Anti-neuraminidase antibody response in serum and nasal secretions following intranasal or subcutaneous inactivated A2-Hong Kong-68 influenza virus vaccine.

Authors:  D S Fedson; R V Fulk; M A Huber; M A Reisberg; J A Kasel
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

7.  Antigenicity of licensed whole virion and subvirion influenza vaccines in "high risk" persons.

Authors:  J A Kasel; R B Couch; H R Six; V Knight
Journal:  Proc Soc Exp Biol Med       Date:  1976-04

8.  Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans.

Authors:  E D Kilbourne; R B Couch; J A Kasel; W A Keitel; T R Cate; J H Quarles; B Grajower; B A Pokorny; B E Johansson
Journal:  Vaccine       Date:  1995-12       Impact factor: 3.641

9.  Host defenses against influenza virus: the role of anti-hemagglutinin antibody.

Authors:  J L Virelizier
Journal:  J Immunol       Date:  1975-08       Impact factor: 5.422

10.  Reduction in plaque size and reduction in plaque number as differing indices of influenza virus-antibody reactions.

Authors:  R I Jahiel; E D Kilbourne
Journal:  J Bacteriol       Date:  1966-11       Impact factor: 3.490

View more
  39 in total

Review 1.  Influenza vaccines: from surveillance through production to protection.

Authors:  Pritish K Tosh; Robert M Jacobson; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2010-01-29       Impact factor: 7.616

Review 2.  The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-06-01       Impact factor: 3.402

Review 3.  Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.

Authors:  Glendie Marcelin; Matthew R Sandbulte; Richard J Webby
Journal:  Rev Med Virol       Date:  2012-03-22       Impact factor: 6.989

4.  Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets.

Authors:  Berend Jan Bosch; Rogier Bodewes; Robert P de Vries; Joost H C M Kreijtz; Willem Bartelink; Geert van Amerongen; Guus F Rimmelzwaan; Cornelis A M de Haan; Albert D M E Osterhaus; Peter J M Rottier
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

5.  Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine.

Authors:  Wilbur H Chen; Alan S Cross; Robert Edelman; Marcelo B Sztein; William C Blackwelder; Marcela F Pasetti
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

Review 6.  Structural basis of influenza virus neutralization.

Authors:  Thomas Han; Wayne A Marasco
Journal:  Ann N Y Acad Sci       Date:  2011-01-11       Impact factor: 5.691

7.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

8.  A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase.

Authors:  Masahiko Hayakawa; Narihiro Toda; Nancy Carrillo; Natalie J Thornburg; James E Crowe; Carlos F Barbas
Journal:  Chembiochem       Date:  2012-09-10       Impact factor: 3.164

9.  Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.

Authors:  Joshua M DiNapoli; Baibaswata Nayak; Lijuan Yang; Brad W Finneyfrock; Anthony Cook; Hanne Andersen; Fernando Torres-Velez; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

10.  Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.

Authors:  E R Job; M Schotsaert; L I Ibañez; A Smet; T Ysenbaert; K Roose; M Dai; C A M de Haan; H Kleanthous; T U Vogel; X Saelens
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.